KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton’s tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:N Engl J Med
Main Authors: Wang, Michael, Munoz, Javier, Goy, Andre, Locke, Frederick L., Jacobson, Caron A., Hill, Brian T., Timmerman, John M., Holmes, Houston, Jaglowski, Samantha, Flinn, Ian W., McSweeney, Peter A., Miklos, David B., Pagel, John M., Kersten, Marie José, Milpied, Noel, Fung, Henry, Topp, Max S., Houot, Roch, Beitinjaneh, Amer, Peng, Weimin, Zheng, Lianqing, Rossi, John M., Jain, Rajul K., Rao, Arati V., Reagan, Patrick M.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731441/
https://ncbi.nlm.nih.gov/pubmed/32242358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1914347
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki